Abstract
Probenecid is used as a uricosuric agent in the treatment of chronic gout and as an adjunct to enhance antibiotic levels in the blood. For research purposes, it is used as a prototypic inhibitor of organic anion transporters and MRPs, including MPR2. The purpose of this research is to study the interaction of probenecid with two other important transporters of the ATP-binding cassette family, Breast Cancer Resistance Protein (BCRP) and P-glycoprotein. These drug efflux transporters are present in the intestine, liver and other organs, and they affect the bioavailability of many compounds. Using the polarized canine kidney cell line MDCK-II and its human MDR1-, BCRP- and murine Bcrp1-transduced subclones, we found that probenecid is transported by mouse Bcrp1 and human BCRP, but not by P-glycoprotein. In addition, flow cytometry experiments showed that probenecid did not affect the accumulation of mitoxantrone in Bcrp1- and BCRPtransduced cells, indicating that this compound was not an effective BCRP/Bcrp1 inhibitor at the concentrations used. We conclude that probenecid is a good substrate of BCRP/Bcrp1, suggesting potential interaction with BCRP/Bcrp1 inhibitors.
Keywords: Probenecid, Breast Cancer Resistance Protein, P-glycoprotein, transport, inhibition
Letters in Drug Design & Discovery
Title: Interaction of Probenecid with the Breast Cancer Resistance Protein Transporter (BCRP/ABCG2)
Volume: 3 Issue: 4
Author(s): G. Merino, R. Real, A. J. Molina, M. M. Pulido, J. G. Prieto and A. I. Alvarez
Affiliation:
Keywords: Probenecid, Breast Cancer Resistance Protein, P-glycoprotein, transport, inhibition
Abstract: Probenecid is used as a uricosuric agent in the treatment of chronic gout and as an adjunct to enhance antibiotic levels in the blood. For research purposes, it is used as a prototypic inhibitor of organic anion transporters and MRPs, including MPR2. The purpose of this research is to study the interaction of probenecid with two other important transporters of the ATP-binding cassette family, Breast Cancer Resistance Protein (BCRP) and P-glycoprotein. These drug efflux transporters are present in the intestine, liver and other organs, and they affect the bioavailability of many compounds. Using the polarized canine kidney cell line MDCK-II and its human MDR1-, BCRP- and murine Bcrp1-transduced subclones, we found that probenecid is transported by mouse Bcrp1 and human BCRP, but not by P-glycoprotein. In addition, flow cytometry experiments showed that probenecid did not affect the accumulation of mitoxantrone in Bcrp1- and BCRPtransduced cells, indicating that this compound was not an effective BCRP/Bcrp1 inhibitor at the concentrations used. We conclude that probenecid is a good substrate of BCRP/Bcrp1, suggesting potential interaction with BCRP/Bcrp1 inhibitors.
Export Options
About this article
Cite this article as:
Merino G., Real R., Molina J. A., Pulido M. M., Prieto G. J. and Alvarez I. A., Interaction of Probenecid with the Breast Cancer Resistance Protein Transporter (BCRP/ABCG2), Letters in Drug Design & Discovery 2006; 3 (4) . https://dx.doi.org/10.2174/157018006776743170
DOI https://dx.doi.org/10.2174/157018006776743170 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chitosan - A Potential Polymer to Prepare Anticancer Drug Delivery Systems: Patent Review
Recent Patents on Anti-Cancer Drug Discovery Toll-Like Receptor (TLR) Response Tolerance: A Key Physiological “ Damage Limitation ” Effect and an Important Potential Opportunity for Therapy
Current Medicinal Chemistry An Overall Picture of Chemokine Receptors: Basic Research and Drug Development
Current Pharmaceutical Design Synthesis of Novel Pyridine Bearing Biologically Active Imidiazolyl, Pyrazolyl, Oxa/thiadiazolyl and Urea Derivatives as Promising Anticancer Agents
Current Organic Synthesis Recent Results in Nonlinear Strain and Modulus Imaging
Current Medical Imaging Detection of Tumor Markers with ProteinChip® Technology
Current Pharmaceutical Biotechnology Antiestrogenic Therapies in Solid Cancers and Multiple Myeloma
Current Molecular Medicine Antitumoral Potential of Lansbermin-I, a Novel Disintegrin from Porthidium lansbergii lansbergii Venom on Breast Cancer Cells
Current Topics in Medicinal Chemistry The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors
Current Cancer Therapy Reviews New Avenue of Research: Antiepileptic Drug and Estradiol Neuroprotection in Epilepsy
Recent Patents on CNS Drug Discovery (Discontinued) Binding of Tris to Bacillus licheniformis α-Amylase Can Affect Its Starch Hydrolysis Activity
Protein & Peptide Letters Diabetes-induced Epigenetic Signature in Vascular Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of COL4A1 in Basement-Membrane Integrity and Cerebral Small-Vessel Disease. The COL4A1 Stroke Syndrome
Current Medicinal Chemistry The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy Development of Lymphatic Vessels: Tumour Lymphangiogenesis and Lymphatic Invasion
Current Medicinal Chemistry Treatment of Squamous Cell Carcinoma of the Head and Neck in the Metastatic and Refractory Settings: Advances in Chemotherapy and the Emergence of Small Molecule Epidermal Growth Factor Receptor Kinase Inhibitors
Current Cancer Drug Targets Nucleic Acid-based Technologies in Therapy of Malignant Gliomas
Current Pharmaceutical Biotechnology The proNGF-p75NTR-Sortilin Signalling Complex as New Target for the Therapeutic Treatment of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Brain Tumor Segmentation Using Deep Belief Networks and Pathological Knowledge
CNS & Neurological Disorders - Drug Targets Medulloblastoma: Role of Developmental Pathways, DNA Repair Signaling, and Other Players
Current Molecular Medicine